12 Million Euros for Biovertis


Vienna - Biovertis AG, a spin-off from Vienna-based Intercell AG, has closed a Series A financing round of up to Euro12 million. In addition, Biovertis has been awarded start-up grants and loans totalling more than Euro5 million over the next years. “We are proud that Biovertis could attract such a significant level of funding, making it one of the largest start-up financings in the last years,” said Alexander von Gabain, CEO of Intercell. The equity funding was provided by Techno Venture Management (TVM), Munich, and by Austrian Kapital & Wert Group who provided silent partnership funds. Erich Felber, co-founder and previously Executive Board member of Micromet AG, Germany, joined the company as CEO. In September 2003, Biovertis was spun-off from Intercell, a leading vaccine company, which retained a 25% equity stake post series A. Biovertis uses Intercell's AIP technology to identify and select bacterial antigens as targets.



Vienna – Apeiron Biologics has entered into an exclusive option with the Cleveland Clinic to license a number of novel compounds that are currently in development there. The drug candidates are designed to fight cancer by...



Vienna – Austrian vaccine specialist Intercell has halted the development of its travellers’ diarrhea vaccine patch after the product failed in a Phase III trial. The company’s management says it will now align its structure to...

Clinical Trial, AustriaAustria


Vienna – Austrian Nabriva Therapeutics AG has recruited 210 patients for a Phase II study with its antibiotic BC-3781, a substance for treating acute bacterial skin infections. In the study, Nabriva will compare response rates of...



Vienna/Darmstadt – Austrian Apeiron Biologics AG has in-licensed Merck's KgaA’s antibody-interleukin fusion protein hu14.18-IL2 for an undisclosed sum. The drug candidate, that is ready to be tested in Phase III studies, binds to...



Vienna – Austrian Affiris AG has bagged EUR368.000 from the Michael J. Fox Foundation within the Parkinson’s Progression Markers Initiative for completion of preclinical development of its PD01 vaccine against Parkinson’s...



Innsbruck – Cholesterol-lowering drugs widely used to prevent heart disease can also boost anti-cancer effect of interleukine-2 (IL-2) immune therapy. When added to tumour cell cultures treated with IL-2, statins dose-dependently...

Displaying results 11 to 20 out of 116

< Previous 11-20 Next >

© 2007-2014 BIOCOM

Product of the week



All Events

Current issue

All issues